Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
University of Toronto
$120,000.00
Developing a Lipid Nanoparticle Platform for Endothelial Gene Delivery in Donor Lungs
FY 2025-26
Summary
Lung transplantation is often the only lifesaving option for people with end-stage lung disease. However, many donor lungs are not suitable for transplant, and even when transplants are performed, complications are common. One promising way to improve donor lungs is by delivering protective or corrective genetic therapies directly into them before transplantation.
Ex vivo lung perfusion (EVLP) is a technique that keeps donor lungs alive and functioning outside the body for several hours. This provides a unique window of opportunity to repair or improve lungs before they are transplanted. To take advantage of this, we need a safe and effective method to deliver therapies into the lung's blood vessels, especially into the cells lining the blood vessels (the endothelium). With the endothelium being the first point of contact between the donor lung and the recipient, it may represent a key target for reducing inflammation, injury, and transplant complications.
My project focuses on developing lipid nanoparticles (LNPs) - tiny, fat-based particles that can carry genetic material safely into cells - as a delivery system for donor lungs during EVLP. LNPs are already proven safe in humans through their use in COVID-19 vaccines, but they have not been optimized for donor lungs in EVLP. I will test LNPs first in cell culture and lung tissue slices, then in rat EVLP, and finally in human donor lungs not suitable for transplant. In each step, I will evaluate how efficiently LNPs reach endothelial cells, whether they remain stable in the EVLP solution, and whether they are safe for lung function.
By creating a reliable delivery platform, this research will open the door for future therapies - such as reducing inflammation, repairing injuries, or even correcting blood type mismatches - to be applied to donor lungs before transplantation. Ultimately, this work aims to expand the donor pool and improve outcomes for patients waiting for a lung transplant.
Department
Program
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
559711
Name
Yune Jenny
Region
Ontario
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Developing a Lipid Nanoparticle Platform for Endothelial Gene Delivery in Donor Lungs
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Acute Toxicity; Endothelial Modification; Ex-Vivo Lung Perfusion (Evlp); Gene Editing; Lipid Nanoparticles (Lnp); Lung Transplantation; Transfection Efficiency
Abstract
Lung transplantation is often the only lifesaving option for people with end-stage lung disease. However, many donor lungs are not suitable for transplant, and even when transplants are performed, complications are common. One promising way to improve donor lungs is by delivering protective or corrective genetic therapies directly into them before transplantation.
Ex vivo lung perfusion (EVLP) is a technique that keeps donor lungs alive and functioning outside the body for several hours. This provides a unique window of opportunity to repair or improve lungs before they are transplanted. To take advantage of this, we need a safe and effective method to deliver therapies into the lung's blood vessels, especially into the cells lining the blood vessels (the endothelium). With the endothelium being the first point of contact between the donor lung and the recipient, it may represent a key target for reducing inflammation, injury, and transplant complications.
My project focuses on developing lipid nanoparticles (LNPs) - tiny, fat-based particles that can carry genetic material safely into cells - as a delivery system for donor lungs during EVLP. LNPs are already proven safe in humans through their use in COVID-19 vaccines, but they have not been optimized for donor lungs in EVLP. I will test LNPs first in cell culture and lung tissue slices, then in rat EVLP, and finally in human donor lungs not suitable for transplant. In each step, I will evaluate how efficiently LNPs reach endothelial cells, whether they remain stable in the EVLP solution, and whether they are safe for lung function.
By creating a reliable delivery platform, this research will open the door for future therapies - such as reducing inflammation, repairing injuries, or even correcting blood type mismatches - to be applied to donor lungs before transplantation. Ultimately, this work aims to expand the donor pool and improve outcomes for patients waiting for a lung transplant.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Yune, Jenny
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~